Trials / Unknown
UnknownNCT00408304
Prevention of Depression With Omega-3 Fatty Acids in Chronic Carriers of Hepatitis C Treated With Interferon Alpha.
- Status
- Unknown
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 60 (planned)
- Sponsor
- Bnai Zion Medical Center · Other Government
- Sex
- All
- Age
- —
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to check whether development of depression as a side effect of interferon alpha treatment in chronic carriers of hepatitis C can be prevented by omega-3 fatty acids.
Detailed description
Omega-3 fatty acids are known as an alternative treatment for different conditions, including mental conditions, such as depression. We assume that combining omega-3 with the treatment by interferon alpha may prevent the development of depression, which is quite a common side effect of the interferon alpha.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | omega-3 fatty acid |
Timeline
- Start date
- 2006-12-01
- Completion
- 2007-12-01
- First posted
- 2006-12-06
- Last updated
- 2006-12-06
Locations
1 site across 1 country: Israel
Source: ClinicalTrials.gov record NCT00408304. Inclusion in this directory is not an endorsement.